Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/51494
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHynd, A.en
dc.contributor.authorRoughead, E.en
dc.contributor.authorPreen, D.en
dc.contributor.authorGlover, J.en
dc.contributor.authorBulsara, M.en
dc.contributor.authorSemmens, J.en
dc.date.issued2009en
dc.identifier.citationAustralian and New Zealand Journal of Public Health, 2009; 33(3):246-252en
dc.identifier.issn1326-0200en
dc.identifier.issn1753-6405en
dc.identifier.urihttp://hdl.handle.net/2440/51494-
dc.descriptionThe definitive version may be found at www.wiley.comen
dc.description.abstract<h4>Objective</h4>To determine whether a 24% increase in patient co-payments in January 2005 and two related co-payment changes for medicines subsidised under the Australian Pharmaceutical Benefits Scheme (PBS) were associated with changes in dispensings in Western Australia (WA).<h4>Method</h4>We analysed aggregate monthly prescription counts and defined daily dose per 1,000 population per day (DDD/1,000/day) for atypical antipsychotics, combination asthma medicines, HmgCoA reductase inhibitors (statins) and proton-pump inhibitors (PPIs). Trends pre and post the co-payment increase in January 2005 were compared.<h4>Results</h4>In three of the four categories examined, prescription counts were significantly lower following the increase in co-payment thresholds. Compared with dispensings prior to the co-payment increase, prescriptions fell by 8% for combination asthma medicines (p<0.001), 9% for PPIs (p<0.001) and 5% for statins (p<0.001). Following the rise in co-payments, DDD/1,000/day decreased for all four categories. Decreases in dispensings to concessional beneficiaries were between 4% and 5% larger than for general beneficiary patients.<h4>Conclusions and implications</h4>The reduction in the both prescription counts and DDD/1,000/day observed for combination asthma medicines, PPIs and statins, which all remained above co-payment thresholds, suggests the increase in PBS co-payments has affected utilisation of these subsidised medicines. The results indicate that increases in patient contributions particularly impact on concessional patients' ability to afford prescription medicines.en
dc.description.statementofresponsibilityAnna Hynd, Elizabeth E. Roughead, David B. Preen, John Glover, Max Bulsara and James Semmensen
dc.language.isoenen
dc.publisherPublic Health Assoc Australia Incen
dc.subjectHumans; Pharmaceutical Preparations; Cost Sharing; Financing, Government; Insurance, Pharmaceutical Services; National Health Programs; Western Australia; Databases as Topicen
dc.titleIncreased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australiaen
dc.typeJournal articleen
dc.identifier.doi10.1111/j.1753-6405.2009.00383.xen
pubs.publication-statusPublisheden
Appears in Collections:Public Health publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.